# Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

> **NCT03285646** · PHASE3 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Chronic Low Back Pain
- Osteoarthritis

## Interventions

- **DRUG:** Fasinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03285646
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-30
- **Primary completion:** 2018-05-05
- **Final completion:** 2019-05-02
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Due to implementation of an urgent safety measure, enrollment and dosing in R475-PN-1612 was stopped; enrolled participants entered the 20-week safety follow-up
- **Last updated:** 2021-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03285646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03285646, "Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03285646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*